Germline genetic variation in an organic anion transporter polypeptide associated with methotrexate pharmacokinetics and clinical effects.

PURPOSE Methotrexate plasma concentration is related to its clinical effects. Our aim was to identify the genetic basis of interindividual variability in methotrexate pharmacokinetics in children with newly diagnosed acute lymphoblastic leukemia (ALL). PATIENTS AND METHODS We performed a genome-wide analysis of 500,568 germline single-nucleotide polymorphisms (SNPs) to identify how inheritance affects methotrexate plasma disposition among 434 children with ALL who received 3,014 courses of methotrexate at 2 to 5 g/m(2). SNPs were validated in an independent cohort of 206 patients. RESULTS Adjusting for age, race, sex, and methotrexate regimen, the most significant associations were with SNPs in the organic anion transporter polypeptide, SLCO1B1. Two SNPs in SLCO1B1, rs11045879 (P = 1.7 x 10(-10)) and rs4149081 (P = 1.7 x 10(-9)), were in linkage disequilibrium (LD) with each other (r(2) = 1) and with a functional polymorphism in SLCO1B1, T521C (rs4149056; r(2) > 0.84). rs11045879 and rs4149081 were validated in an independent cohort of 206 patients (P = .018 and P = .017), as were other SLCO1B1 SNPs residing in different LD blocks. SNPs in SLCO1B1 were also associated with GI toxicity (odds ratio, 15.3 to 16.4; P = .03 to .004). CONCLUSION A genome-wide interrogation identified inherited variations in a plausible, yet heretofore low-priority candidate gene, SLCO1B1, as important determinants of methotrexate's pharmacokinetics and clinical effects.

[1]  D. Bates,et al.  Mixed-Effects Models in S and S-PLUS , 2001 .

[2]  C. Pui,et al.  Renal Function and Methotrexate Clearance in Children With Newly Diagnosed Leukemia , 1995, Pharmacotherapy.

[3]  Jonathan C. Cohen,et al.  Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. , 2006, The New England journal of medicine.

[4]  Kaoru Kobayashi,et al.  Functional characterization of SLCO1B1 (OATP-C) variants, SLCO1B1*5, SLCO1B1*15 and SLCO1B1*15+C1007G, by using transient expression systems of HeLa and HEK293 cells , 2005, Pharmacogenetics and genomics.

[5]  Low-dose versus high-dose methotrexate during remission induction in childhood acute lymphoblastic leukemia (Protocol 81-01 update). , 1991 .

[6]  P. Fearnhead,et al.  Genome-wide association study of prostate cancer identifies a second risk locus at 8q24 , 2007, Nature Genetics.

[7]  Y. Sugiyama,et al.  Vectorial Transport of Enalapril by Oatp1a1/Mrp2 and OATP1B1 and OATP1B3/MRP2 in Rat and Human Livers , 2006, Journal of Pharmacology and Experimental Therapeutics.

[8]  D. Reich,et al.  Principal components analysis corrects for stratification in genome-wide association studies , 2006, Nature Genetics.

[9]  G. Peters,et al.  Disparate mechanisms of antifolate resistance provoked by methotrexate and its metabolite 7-hydroxymethotrexate in leukemia cells: implications for efficacy of methotrexate therapy. , 2004, Blood.

[10]  M. Relling,et al.  Patient characteristics associated with high-risk methotrexate concentrations and toxicity. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  Howard L McLeod,et al.  Pharmacogenomics--drug disposition, drug targets, and side effects. , 2003, The New England journal of medicine.

[12]  M. Krajinovic,et al.  Polymorphism G80A in the reduced folate carrier gene and its relationship to methotrexate plasma levels and outcome of childhood acute lymphoblastic leukemia. , 2002, Blood.

[13]  M. Relling,et al.  Conventional compared with individualized chemotherapy for childhood acute lymphoblastic leukemia. , 1998, The New England journal of medicine.

[14]  Conrad C. Huang,et al.  Interaction of Methotrexate with Organic-Anion Transporting Polypeptide 1A2 and Its Genetic Variants , 2006, Journal of Pharmacology and Experimental Therapeutics.

[15]  N. Olsen,et al.  New drugs for rheumatoid arthritis. , 2004, The New England journal of medicine.

[16]  William E. Evans,et al.  Acute lymphoblastic leukaemia: a model for the pharmacogenomics of cancer therapy , 2006, Nature Reviews Cancer.

[17]  Paul Scheet,et al.  A fast and flexible statistical model for large-scale population genotype data: applications to inferring missing genotypes and haplotypic phase. , 2006, American journal of human genetics.

[18]  M. Link,et al.  Methotrexate-induced renal impairment: clinical studies and rescue from systemic toxicity with high-dose leucovorin and thymidine. , 1983, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  M. Relling,et al.  Clinical pharmacodynamic studies of high-dose methotrexate in acute lymphocytic leukemia. , 2009, NCI monographs : a publication of the National Cancer Institute.

[20]  W. Sandborn,et al.  Systemic and intestinal pharmacokinetics of methotrexate in patients with inflammatory bowel disease , 1999, Clinical pharmacology and therapeutics.

[21]  T. Abe,et al.  LST-2, a human liver-specific organic anion transporter, determines methotrexate sensitivity in gastrointestinal cancers. , 2001, Gastroenterology.

[22]  Mikko Niemi,et al.  Role of OATP transporters in the disposition of drugs. , 2007, Pharmacogenomics.

[23]  M. Kamm,et al.  Bone marrow toxicity caused by azathioprine in inflammatory bowel disease: 27 years of experience. , 1993, Gut.

[24]  Wooin Lee,et al.  A common polymorphism in the bile acid receptor farnesoid X receptor is associated with decreased hepatic target gene expression. , 2007, Molecular endocrinology.

[25]  E. Cook,et al.  Ancestry and pharmacogenetics of antileukemic drug toxicity. , 2007, Blood.

[26]  H. Yawo,et al.  Identification of a Novel Gene Family Encoding Human Liver-specific Organic Anion Transporter LST-1* , 1999, The Journal of Biological Chemistry.

[27]  M. Krajinovic,et al.  Pharmacogenetics of methotrexate. , 2004, Pharmacogenomics.

[28]  C. Allaart,et al.  A clinical pharmacogenetic model to predict the efficacy of methotrexate monotherapy in recent-onset rheumatoid arthritis. , 2007, Arthritis and rheumatism.

[29]  Russ Altman,et al.  Pharmacogenomics: Challenges and Opportunities , 2006, Annals of Internal Medicine.

[30]  U. Meyer.  Pharmacogenetics and adverse drug reactions , 2000, The Lancet.

[31]  D. Gudbjartsson,et al.  Two variants on chromosome 17 confer prostate cancer risk, and the one in TCF2 protects against type 2 diabetes , 2007, Nature Genetics.

[32]  M. Relling,et al.  Late-onset delayed excretion of methotrexate , 2004, Cancer Chemotherapy and Pharmacology.

[33]  W. Bowman,et al.  METHOTREXATE SYSTEMIC CLEARANCE INFLUENCES PROBABILITY OF RELAPSE IN CHILDREN WITH STANDARD-RISK ACUTE LYMPHOCYTIC LEUKAEMIA , 1984, The Lancet.

[34]  M. Relling,et al.  Moving towards individualized medicine with pharmacogenomics , 2004, Nature.

[35]  Shigeki Sugiura,et al.  ROLE OF ORGANIC ANION TRANSPORTER OATP1B1 (OATP-C) IN HEPATIC UPTAKE OF IRINOTECAN AND ITS ACTIVE METABOLITE, 7-ETHYL-10-HYDROXYCAMPTOTHECIN: IN VITRO EVIDENCE AND EFFECT OF SINGLE NUCLEOTIDE POLYMORPHISMS , 2005, Drug Metabolism and Disposition.

[36]  N. Jaffe,et al.  High-dose methotrexate in osteosarcoma: let the questions surcease--time for final acceptance. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[37]  W. Evans,et al.  Pharmacogenomics of acute lymphoblastic leukemia , 2006, Current opinion in hematology.

[38]  S L George,et al.  Clinical pharmacodynamics of high-dose methotrexate in acute lymphocytic leukemia. Identification of a relation between concentration and effect. , 1986, The New England journal of medicine.

[39]  G. Peters,et al.  Effect of polymorphisms in folate-related genes on in vitro methotrexate sensitivity in pediatric acute lymphoblastic leukemia. , 2005, Blood.

[40]  J. Shuster,et al.  Intermediate-dose intravenous methotrexate and mercaptopurine therapy for non-T, non-B acute lymphocytic leukemia of childhood: a Pediatric Oncology Group study. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[41]  C. Gieger,et al.  Genomewide association analysis of coronary artery disease. , 2007, The New England journal of medicine.

[42]  R. Kim,et al.  Effect of drug transporter genotypes on pravastatin disposition in European- and African-American participants , 2007, Pharmacogenetics and genomics.

[43]  S. Meltzer,et al.  6-Mercaptopurine in the management of inflammatory bowel disease: short- and long-term toxicity. , 1989, Annals of internal medicine.

[44]  P. Neuvonen,et al.  Different Effects of SLCO1B1 Polymorphism on the Pharmacokinetics of Atorvastatin and Rosuvastatin , 2007, Clinical pharmacology and therapeutics.

[45]  B. Burkhardt,et al.  The impact of the methotrexate administration schedule and dose in the treatment of children and adolescents with B-cell neoplasms: a report of the BFM Group Study NHL-BFM95. , 2004, Blood.

[46]  A. Tsiatis,et al.  Pharmacokinetics of sustained serum methotrexate concentrations secondary to gastrointestinal obstruction. , 1981, Journal of pharmaceutical sciences.

[47]  E. Cook,et al.  Homocysteine, pharmacogenetics, and neurotoxicity in children with leukemia. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[48]  D. Goldstein.  Pharmacogenetics in the laboratory and the clinic. , 2003, New England Journal of Medicine.

[49]  R. Kim,et al.  Polymorphisms in OATP-C , 2001, The Journal of Biological Chemistry.

[50]  Marc Ansari,et al.  Pharmacogenomics in cancer treatment defining genetic bases for inter-individual differences in responses to chemotherapy , 2007, Current opinion in pediatrics.

[51]  Joseph T. Glessner,et al.  A genome-wide association study identifies KIAA0350 as a type 1 diabetes gene , 2007, Nature.

[52]  R. Kim,et al.  Intestinal Drug Transporter Expression and the Impact of Grapefruit Juice in Humans , 2007, Clinical pharmacology and therapeutics.

[53]  R. Gray.  A Class of $K$-Sample Tests for Comparing the Cumulative Incidence of a Competing Risk , 1988 .

[54]  G. Curt,et al.  The pharmacology and clinical use of methotrexate. , 1983, The New England journal of medicine.

[55]  P. Neuvonen,et al.  High plasma pravastatin concentrations are associated with single nucleotide polymorphisms and haplotypes of organic anion transporting polypeptide-C (OATP-C, SLCO1B1). , 2004, Pharmacogenetics.

[56]  Cheng Cheng,et al.  Treating childhood acute lymphoblastic leukemia without cranial irradiation. , 2009, The New England journal of medicine.

[57]  Cheng Cheng,et al.  Improved outcome for children with acute lymphoblastic leukemia: results of Total Therapy Study XIIIB at St Jude Children's Research Hospital. , 2004, Blood.